Cubeddu 1988.

Methods	2‐week screening period; 4‐week single‐blind placebo run‐in period; inclusion criteria=supine and standing DBP >95 mm Hg during screening period, and supine and standing DBP >90 mm Hg during screening period and placebo run‐in; 9‐week double‐blind treatment, consisting of 3 upward titration schedules up to pre‐assigned dose of doxazosin (2, 4, or 8 mg) or placebo; this titration schedule was followed until "goal" BP was achieved, defined as reduction in supine or standing diastolic BP of ≥10 mm Hg from baseline and to less than 90 mm Hg at 24h postdose; if adverse effects (limiting or persisting side effects) or significant laboratory toxicity prevented further upward titration, then patient was discontinued from study
Participants	Doxazosin 2 mg: n=38 (25 males, 13 females); 26 white, 11 black, 1 other; mean age=52.4 (range 28‐68) years; n=34 with baseline BP reported; baseline standing SBP=150.5 mm Hg, DBP=102.2 mm Hg, HR=79.6 bpm; baseline supine BP=152.7 mm Hg, DBP=98.8 mm Hg, HR=73.1 bpm Doxazosin 4 mg: n=31 (20 males, 11 females); 22 white, 9 black; mean age=50.6 (range 32‐66) years; n=25 with baseline BP reported; baseline standing SBP=147.4 mm Hg, DBP=102.2 mm Hg, HR=80.0 bpm; baseline supine BP=149.4 mm Hg, DBP=99.8 mm Hg, HR=71.9 bpm Doxazosin 8 mg: n=33 (17 males, 16 females); 19 white, 13 black, 1 not recorded; mean age=49.4 (range 26‐66) years; n=25 with baseline BP reported; baseline baseline standing SBP=147.5 mm Hg, DBP=102.4 mm Hg, HR=79.6 bpm; baseline supine BP=150.3 mm Hg, DBP=99.9 mm Hg, HR=72.9 bpm Placebo: n=33 (22 males, 11 females); 18 white, 15 black; mean age=50.5 (range 33‐71) years; n=30 with baseline BP reported; baseline standing SBP=140.9 mm Hg, DBP=99.7 mm Hg, HR=84.5 bpm; baseline supine BP=145.8 mm Hg, DBP=98.8 mm Hg, HR=76.5 bpm
Interventions	Doxazosin 2 mg once daily Doxazosin 4 mg once daily Doxazosin 8 mg once daily Placebo Taken upon awakening
Outcomes	Trough standing SBP/DBP using mercury sphygmomanometer Trough supine SBP/DBP using mercury sphygmomanometer Peak standing SBP/DBP using mercury sphygmomanometer Trough standing HR Trough supine HR Peak standing HR WDAE
Notes	BP change and SE of change reported, endpoint BP reported, endpoint SD not reported, baseline BP reported, baseline SD not reported; calculated SD of change from N and SE of change; BP and HR data from Table 5, p. 163 Mean doxazosin doses prior to final BP observation were 2, 4, and 7.7 mg for 2, 4, and 8 mg groups, respectively; 1 of 34 patients in 2 mg group was receiving 1 mg doxazosin and only 2 of 25 patients in 8 mg group were receiving a lower dose (4 mg)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	21/135 patients (4/38 doxazosin 2 mg; 6/31 doxazosin 4 mg; 8/33 doxazosin 8 mg; 3/33 placebo) who "discontinued during the double‐blind period" not included in efficacy analysis. Reasons for discontinuations not described.
Selective reporting (reporting bias)	Low risk	BP lowering efficacy was primary outcome. HR and safety/tolerability data reported.
Other bias	Unclear risk	Funding source not reported.